Mantle Cell Lymphoma | Specialty

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

January 6th 2021

James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

January 4th 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Dr. Jain on the Responses Elicited With Ibrutinib/Rituximab in Previously Untreated MCL

December 24th 2020

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

Dr. Lee on the Safety, Efficacy of Cirmtuzumab/Ibrutinib Combo in MCL

December 24th 2020

Hun Ju Lee, MD, discusses responses to cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma.

Early MRD Monitoring in Younger Patients With MCL Posttransplant Predicts Outcomes

December 22nd 2020

December 22, 2020 - Minimum residual disease negativity in the bone marrow and peripheral blood prior to autologous stem cell transplant predicts better progression-free survival and overall survival in younger patients with mantle cell lymphoma.

Dr. Jain on the Role of BTK Inhibitors in MCL

December 21st 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

Sequential Immunotherapy May Not Be Optimal Treatment for TP53+ MCL, But Potentially TP53 Wild-Type Disease

December 18th 2020

December 18, 2020 - Sequential immunotherapy with rituximab-based therapy and the addition of lenalidomide proved effective among patients with TP53 wild-type mantle cell lymphoma, even among those with a Ki-67 level of at least 30% and/or blastoid morphology.

Liso-Cel Proves to Be Highly Active, Tolerable in Relapsed/Refractory MCL

December 17th 2020

December 17, 2020 - Lisocabtagene maraleucel exhibited promising antitumor activity with low rates of grade 3 or higher cytokine release syndrome and neurotoxicity in patients with relapsed/refractory mantle cell lymphoma.

KTE-X19 Approved in Europe for Relapsed/Refractory MCL

December 17th 2020

December 17, 2020 — The European Commission has granted a conditional marketing authorization to the CD19-targeted CAR T-cell therapy KTE-X19 for use in adult patients with relapsed or refractory mantle cell lymphoma who had previously received 2 or more lines of systemic therapy including a BTK inhibitor.

Dr. Hill on the Safety Profiles of BTK Inhibitors in MCL

December 7th 2020

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Jain on the Rationale to Evaluate Ibrutinib/Rituximab in MCL

December 7th 2020

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

First-in-Human Trial Demonstrates Clinical Activity With ROR1-Directed ADC in MCL and DLBCL

December 5th 2020

December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.

Dr. Ruan on Future Research With CAR T-Cell Therapy in MCL

December 4th 2020

Jia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.

MCL Treatment Shifts Away from Chemoimmunotherapy, Enters New Era of Novel Agents and Cellular Therapies

December 4th 2020

With the shift away from chemoimmunotherapy, and the adoption of novel combinations, as well as cellular therapy, the MCL treatment landscape has entered a new era. Looking forward, minimal residual disease is bound to play a critical role in terms of guiding treatment selection.

Dr. Brody on the Expanding Role of Venetoclax in MCL

December 3rd 2020

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Dr. Hill on the Utility of BTK Inhibitors in Relapsed/Refractory MCL

December 2nd 2020

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.